HIV Protease inhibitors impact on apoptosis

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

HIV protease inhibitors are the backbone of HIV therapy. In addition to blocking intracellular HIV protease and dramatically decreasing viral burden, the protease inhibitors also regulate apoptosis. A growing body of data has confirmed the immunomodulatory effects of HIV protease inhibitors which block CD4+ and CD8+ T cell death in models of HIV infection. The mechanism of this apoptosis inhibition is still under active investigation and supported by several proposed hypothesis for how they alter the fate of the cell. More recently, the anti-apoptotic effects of the HIV protease inhibitors has been extended to the non-HIV, non-immune cell, whereby protease inhibitors prevent apoptosis, and disease, in animal models of sepsis, hepatitis and stroke. Interestingly, when HIV protease inhibitors are used at supra-therapeutic concentrations, they exert pro-apoptotic effects. This has been demonstrated in a number of tumor models. Although it is unclear how HIV protease inhibitors can induce apoptosis at increased concentrations, future research will define the targets of the immunomodulation and reveal the full clinical potential of this intriguing class of drugs.

Original languageEnglish (US)
Pages (from-to)75-79
Number of pages5
JournalMedicinal Chemistry
Volume4
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

HIV Protease Inhibitors
Apoptosis
Protease Inhibitors
HIV Protease
Animal Disease Models
Immunomodulation
Viral Load
Hepatitis
HIV Infections
Sepsis
Cell Death
Stroke
HIV
T-Lymphocytes
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • CD4 T cells
  • Highly active anti-retroviral therapy
  • HIV replication
  • Immune system
  • Nelfinavir

ASJC Scopus subject areas

  • Drug Discovery

Cite this

HIV Protease inhibitors impact on apoptosis. / Rizza, Stacey; Badley, Andrew David.

In: Medicinal Chemistry, Vol. 4, No. 1, 01.2008, p. 75-79.

Research output: Contribution to journalArticle

@article{cb967103ff2e46a6b34f27c4d2c60218,
title = "HIV Protease inhibitors impact on apoptosis",
abstract = "HIV protease inhibitors are the backbone of HIV therapy. In addition to blocking intracellular HIV protease and dramatically decreasing viral burden, the protease inhibitors also regulate apoptosis. A growing body of data has confirmed the immunomodulatory effects of HIV protease inhibitors which block CD4+ and CD8+ T cell death in models of HIV infection. The mechanism of this apoptosis inhibition is still under active investigation and supported by several proposed hypothesis for how they alter the fate of the cell. More recently, the anti-apoptotic effects of the HIV protease inhibitors has been extended to the non-HIV, non-immune cell, whereby protease inhibitors prevent apoptosis, and disease, in animal models of sepsis, hepatitis and stroke. Interestingly, when HIV protease inhibitors are used at supra-therapeutic concentrations, they exert pro-apoptotic effects. This has been demonstrated in a number of tumor models. Although it is unclear how HIV protease inhibitors can induce apoptosis at increased concentrations, future research will define the targets of the immunomodulation and reveal the full clinical potential of this intriguing class of drugs.",
keywords = "CD4 T cells, Highly active anti-retroviral therapy, HIV replication, Immune system, Nelfinavir",
author = "Stacey Rizza and Badley, {Andrew David}",
year = "2008",
month = "1",
doi = "10.2174/157340608783331443",
language = "English (US)",
volume = "4",
pages = "75--79",
journal = "Medicinal Chemistry",
issn = "1573-4064",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - HIV Protease inhibitors impact on apoptosis

AU - Rizza, Stacey

AU - Badley, Andrew David

PY - 2008/1

Y1 - 2008/1

N2 - HIV protease inhibitors are the backbone of HIV therapy. In addition to blocking intracellular HIV protease and dramatically decreasing viral burden, the protease inhibitors also regulate apoptosis. A growing body of data has confirmed the immunomodulatory effects of HIV protease inhibitors which block CD4+ and CD8+ T cell death in models of HIV infection. The mechanism of this apoptosis inhibition is still under active investigation and supported by several proposed hypothesis for how they alter the fate of the cell. More recently, the anti-apoptotic effects of the HIV protease inhibitors has been extended to the non-HIV, non-immune cell, whereby protease inhibitors prevent apoptosis, and disease, in animal models of sepsis, hepatitis and stroke. Interestingly, when HIV protease inhibitors are used at supra-therapeutic concentrations, they exert pro-apoptotic effects. This has been demonstrated in a number of tumor models. Although it is unclear how HIV protease inhibitors can induce apoptosis at increased concentrations, future research will define the targets of the immunomodulation and reveal the full clinical potential of this intriguing class of drugs.

AB - HIV protease inhibitors are the backbone of HIV therapy. In addition to blocking intracellular HIV protease and dramatically decreasing viral burden, the protease inhibitors also regulate apoptosis. A growing body of data has confirmed the immunomodulatory effects of HIV protease inhibitors which block CD4+ and CD8+ T cell death in models of HIV infection. The mechanism of this apoptosis inhibition is still under active investigation and supported by several proposed hypothesis for how they alter the fate of the cell. More recently, the anti-apoptotic effects of the HIV protease inhibitors has been extended to the non-HIV, non-immune cell, whereby protease inhibitors prevent apoptosis, and disease, in animal models of sepsis, hepatitis and stroke. Interestingly, when HIV protease inhibitors are used at supra-therapeutic concentrations, they exert pro-apoptotic effects. This has been demonstrated in a number of tumor models. Although it is unclear how HIV protease inhibitors can induce apoptosis at increased concentrations, future research will define the targets of the immunomodulation and reveal the full clinical potential of this intriguing class of drugs.

KW - CD4 T cells

KW - Highly active anti-retroviral therapy

KW - HIV replication

KW - Immune system

KW - Nelfinavir

UR - http://www.scopus.com/inward/record.url?scp=40049103926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40049103926&partnerID=8YFLogxK

U2 - 10.2174/157340608783331443

DO - 10.2174/157340608783331443

M3 - Article

C2 - 18220972

AN - SCOPUS:40049103926

VL - 4

SP - 75

EP - 79

JO - Medicinal Chemistry

JF - Medicinal Chemistry

SN - 1573-4064

IS - 1

ER -